Skip to main content
. 2021 Apr 30;40:148. doi: 10.1186/s13046-021-01943-5

Fig. 8.

Fig. 8

MELK inhibitor (OTSSP167) attenuates BBOX1-AS1-mediated carcinogenicity in NSCLC cells. a-e OTSSP167 (50 nM) was used to treat A549 and SK-MES-1 cells prior to transfection with pcDNA-MELK. a Cell viability was determined by CCK-8 assays. b Colony formation assays were used to assess cell proliferation ability. c and d Wound healing and transwell assays were applied to evaluate cell migration and invasion. e Western blot assays were performed to detect EMT-related protein expression. *P < 0.05, **P < 0.01, ***P < 0.001